BR112021003807A8 - Herpesvírus quimérico oncolítico que estimula uma resposta imune antitumoral - Google Patents

Herpesvírus quimérico oncolítico que estimula uma resposta imune antitumoral

Info

Publication number
BR112021003807A8
BR112021003807A8 BR112021003807A BR112021003807A BR112021003807A8 BR 112021003807 A8 BR112021003807 A8 BR 112021003807A8 BR 112021003807 A BR112021003807 A BR 112021003807A BR 112021003807 A BR112021003807 A BR 112021003807A BR 112021003807 A8 BR112021003807 A8 BR 112021003807A8
Authority
BR
Brazil
Prior art keywords
herpesvirus
nucleic acid
oncolytic
stimulates
immune response
Prior art date
Application number
BR112021003807A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021003807A2 (pt
Inventor
C Roth Justin
A Cassady Kevin
Original Assignee
The Res Institute At Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Res Institute At Nationwide Childrens Hospital filed Critical The Res Institute At Nationwide Childrens Hospital
Publication of BR112021003807A2 publication Critical patent/BR112021003807A2/pt
Publication of BR112021003807A8 publication Critical patent/BR112021003807A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021003807A 2018-08-31 2019-08-30 Herpesvírus quimérico oncolítico que estimula uma resposta imune antitumoral BR112021003807A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725809P 2018-08-31 2018-08-31
US62/725,809 2018-08-31
PCT/US2019/049047 WO2020047398A1 (en) 2018-08-31 2019-08-30 Chimeric oncolytic herpesvirus that stimulate an antitumor immune response

Publications (2)

Publication Number Publication Date
BR112021003807A2 BR112021003807A2 (pt) 2021-05-18
BR112021003807A8 true BR112021003807A8 (pt) 2022-04-19

Family

ID=69643794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021003807A BR112021003807A8 (pt) 2018-08-31 2019-08-30 Herpesvírus quimérico oncolítico que estimula uma resposta imune antitumoral

Country Status (10)

Country Link
EP (1) EP3843761A4 (ja)
JP (1) JP2021534786A (ja)
KR (1) KR20210053923A (ja)
CN (1) CN113396217A (ja)
AU (1) AU2019333181A1 (ja)
BR (1) BR112021003807A8 (ja)
CA (1) CA3110406A1 (ja)
IL (1) IL281085A (ja)
SG (1) SG11202101829UA (ja)
WO (1) WO2020047398A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096996A2 (en) 2021-11-24 2023-06-01 Research Institute At Nationwide Children's Hospital Chimeric hsv expressing hil21 to boost anti-tumor immune activity
WO2023235377A1 (en) * 2022-05-31 2023-12-07 The Research Institute At Nationwide Children's Hospital Il-27 expressing oncolytic viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO2007005876A2 (en) * 2005-07-01 2007-01-11 The Uab Research Foundation Chimeric herpes viruses and uses thereof

Also Published As

Publication number Publication date
JP2021534786A (ja) 2021-12-16
WO2020047398A1 (en) 2020-03-05
SG11202101829UA (en) 2021-03-30
AU2019333181A1 (en) 2021-03-18
KR20210053923A (ko) 2021-05-12
EP3843761A4 (en) 2022-06-08
IL281085A (en) 2021-04-29
CA3110406A1 (en) 2020-03-05
WO2020047398A9 (en) 2020-04-30
EP3843761A1 (en) 2021-07-07
CN113396217A (zh) 2021-09-14
BR112021003807A2 (pt) 2021-05-18

Similar Documents

Publication Publication Date Title
Jost et al. Changes in cytokine levels and NK cell activation associated with influenza
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
PH12020551437A1 (en) Methods for treating hpv-associated diseases
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
MX2023008067A (es) Virus vaccinia atenuados competentes para replicacion con delecion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
BR112021003807A8 (pt) Herpesvírus quimérico oncolítico que estimula uma resposta imune antitumoral
CA3060516A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
Buijs et al. Recombinant immunomodulating lentogenic or mesogenic oncolytic Newcastle disease virus for treatment of pancreatic adenocarcinoma
Elboim et al. HSV-2 specifically down regulates HLA-C expression to render HSV-2-infected DCs susceptible to NK cell killing
BR112019005025A8 (pt) Sistema e método para caracterizar um painel
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
BR112021021542A2 (pt) Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
JOP20210051A1 (ar) علاج للسرطان بواسطة استخدم توليفة من فيروس الوقس الحال للورم ومثبط نقاط الفحص المناعي، وتركيبة صيدلانية ودواء توليفي للاستخدام في علاج السرطان
WO2019202401A3 (en) Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer
BR112017019776A2 (pt) proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
Depierreux et al. Selective modulation of cell surface proteins during vaccinia infection: A resource for identifying viral immune evasion strategies
MX2020007676A (es) Antígenos t grandes y pequeños del poliomavirus de células de merkel, construcciones de ácido nucleico y vacunas fabricadas con ellos, y métodos de usar los mismos.
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
MX2022001781A (es) Metodos de terapia celular.